Clinical trials: Hyperkalemia
Cirrhosis, Ascites
Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
The question whether the sequential diuretic therapy, that means using an antialdosteronic drug at first and adding a loop diuretic in nonresponders, is better than the combination of the two diuretics from the beginning…
- Trial name
- SVSSF (NCT00741663)
- Testing
- Spironolactone and furosemide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Padova
Acute Renal Failure, Chronic Renal Failure
How Much Reliable iv Calcium for the Treatment of Hyperkalemia?
Hyperkalemia is a common problem in the emergency services and one of the life threatening metabolic emergencies. Calcium, insulin, beta adrenoceptor agonists, bicarbonate, diuretics, sodium polystyrene sulfonate and lastly…
- Trial name
- NCT02672930
- Testing
- Electrocardiogram (ECG)
- Where
- Turkey (Türkiye)
- Volunteers
- 111 people
- Sponsor
- Haseki Training and Research Hospital
Heart Failure, Hyperkalemia
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia
The CARE-HK in HF is a registry study based on the hypothesis that adherence to guidelines is associated with improved real-world outcomes for heart failure (HF) patients.
- Trial name
- CARE-HK (NCT04864795)
- Where
- 116 sites in United States, Austria and 5 more
- Volunteers
- 2,636 people
- Sponsor
- Vifor (International) Inc.
Peritoneal Dialysis
Effects of Renin-Angiotensin System Inhibitors in Peritoneal Dialysis Patients
Among antihypertensive medications, RAS inhibitor classes, namely angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) have the most prospective data on mortality and cardiovascular outcomes in…
- Trial name
- NCT04076930
- Testing
- angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)
- Where
- Thailand
- Volunteers
- 1,468 people
- Sponsor
- Chiang Mai University
Hyperkalemia, Resistant Hypertension
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone…
- Trial name
- AMBER (NCT03071263)
- Testing
- Patiromer, Spironolactone
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 295 people
- Sponsor
- Relypsa, Inc.
ESRD, Hyperkalemia
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia (potassium greater than 5 milliequivalents per liter) is a non-randomized, crossover study.
- Conditions
- ESRD, Hyperkalemia, End Stage Renal Disease
- Trial name
- NCT03326583
- Testing
- Patiromer
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dominic Raj
Hyperkalemia
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - < 18 years of age with chronic kidney…
- Trial name
- EMERALD (NCT03087058)
- Testing
- Patiromer
- Where
- 30 sites in United States, Bulgaria and 5 more
- Volunteers
- 23 people
- Sponsor
- Vifor Pharma, Inc.
Hyperkalemia
Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
To investigate the efficacy of each ZG-801 starting dose and the titration algorithm of ZG-801 for the treatment of hyperkalemia in Japanese patients. To evaluate the safety of ZG-801 for the chronic use (total over 52 weeks).
- Trial name
- NCT03799926
- Testing
- patiromer
- Where
- Japan
- Volunteers
- 184 people
- Sponsor
- Zeria Pharmaceutical
Diabetic Nephropathy
Aldosterone in Diabetic Nephropathy
The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.
- Trial name
- ALDODN (NCT00870402)
- Testing
- Spironolactone
- Where
- Chile
- Volunteers
- 160 people
- Sponsor
- Universidad de los Andes, Chile
Hyperkalemia
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other.
- Trial name
- PLATINUM (NCT04443608)
- Testing
- Patiromer Powder for Oral Suspension [Veltassa]
- Where
- 19 sites in United States
- Volunteers
- 115 people
- Sponsor
- Comprehensive Research Associates
Hyperkalemia
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic…
- Trial name
- DIALIZE China (NCT04217590)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 36 sites in China
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Hyperkalemia, Chronic Kidney Disease(CKD)
Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community
The goal of this observational study is to investigate the prevalence and risk factors of hyperkalemia in community-based non-dialysis chronic kidney disease (CKD) patients. The main questions it aims to answer are: 1.
- Trial name
- NCT06940414
- Testing
- No Intervention
- Where
- China
- Volunteers
- 1,890 people
- Sponsor
- Xiujuan Zang
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Hyperkalemia
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
- Trial name
- NCT02033317
- Testing
- patiromer
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Relypsa, Inc.
Hyperkalaemia
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more…
- Trial name
- GRAZE (NCT04997161)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
CKD, Diabetes Mellitus, Type 2
The ORTIZ Study: Optimising RASi Therapy With SZC
The hypothesis is that 3 months' treatment with SZC versus placebo will enable RASi (Irbesartan) maximisation in a cohort of patients with diabetic kidney disease.
- Conditions
- CKD, Diabetes Mellitus, Type 2, Hyperkalemia
- Trial name
- ORTIZ (NCT04983979)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Barts & The London NHS Trust
Hyperkalemia
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of…
- Trial name
- ADAPT (NCT05535920)
- Testing
- LOKELMA 5 GM Powder for Oral Suspension
- Where
- 5 sites in United States
- Volunteers
- 88 people
- Sponsor
- NephroNet, Inc.
Hyperkalemia
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and…
- Trial name
- NCT06277128
- Testing
- WS016 3g, WS016 6g, WS016 12g
- Where
- 26 sites in China
- Volunteers
- 140 people
- Sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.
Diabetic Nephropathy
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
Introduction: Aldosterone seems to have deleterious effects on the kidneys. Many animal studies and few clinical trials now have shown that suppression of aldosterone by aldosterone receptor blockers ameliorated these effects.
- Trial name
- NCT00498537
- Testing
- spironolactone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- US Department of Veterans Affairs
Liver Transplantation
Nebulized Salbutamol Facilitate Management of Hyperkalemia Postreperfusion During Liver Transplantation
The therapeutic effect of nebulized salbutamol on hyperkalemia during reperfusion in liver transplantation patients. Secondary research objectives: To observe the results of blood gas analysis, changes in urinary potassium and…
- Trial name
- NCT05589441
- Testing
- salbutamol, Insulin
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University